Ruscica, Massimiliano

PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor

Da Dalt, L., Ruscica, M., Bonacina, F., Balzarotti, G., Dhyani, A., Di Cairano, E., Baragetti, A., Arnaboldi, L., De Metrio, S., Pellegatta, F., et al. (2019) · European Heart Journal

Pancreatic function and diabetesLipid metabolism and disorders

Cited by 209

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019) · Drugs

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 132

Parthenolide Inhibits the LPS‐induced Secretion of IL‐6 and TNF‐α and NF‐κB Nuclear Translocation in BV‐2 Microglia

Magni, P., Ruscica, M., Dozio, E., Rizzi, E., Beretta, G., & Facino, R. M. (2012) · Phytotherapy Research

Sesquiterpenes and Asteraceae StudiesNeuroinflammation and Neurodegeneration Mechanisms

Cited by 80

Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease

Zimetti, F., Caffarra, P., Ronda, N., Favari, E., Adorni, M. P., Zanotti, I., Bernini, F., Barocco, F., Spallazzi, M., Galimberti, D., et al. (2016) · Journal of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 75

Lipid Lowering Drugs: Present Status and Future Developments

Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 73

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease

Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 67

Depression and cardiovascular risk-association among Beck depression inventory, PCSK9 levels and insulin resistance

Macchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiac Health and Mental Health

Cited by 51

Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis

Ruscica, M., Busnelli, M., Runfola, E., Corsini, A., & Sirtori, C. R. (2019) · International Journal of Molecular Sciences

Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphisms

Cited by 33

Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy

Cesaro, A., Acerbo, V., Scialla, F., Zito, A., Porcelli, G., Panico, D., Argenziano, G., Iaria, D., Monaco, M. G., De Sio, V., et al. (2026) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 11

From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: A Monte Carlo simulation within the ITACARE-P registry

Faggiano, A., Maloberti, A., Ambrosetti, M., Giallauria, F., Mureddu, G., Venturini, E., Ruzzolini, M., Maranta, F., Vatri, M., Zadre, L., et al. (2026) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCoronary Interventions and Diagnostics

Cited by 10

Cyclase-associated protein 2 (CAP2) controls MRTF-A localization and SRF activity in mouse embryonic fibroblasts

Kepser, L.-J., Khudayberdiev, S., Hinojosa, L. S., Macchi, C., Ruscica, M., Marcello, E., Culmsee, C., Grosse, R., & Rust, M. B. (2021) · Scientific Reports

Cellular Mechanics and InteractionsProtein Kinase Regulation and GTPase Signaling

Cited by 9